Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19042240 | INTEGRATIVE PLASMID | January 2025 | February 2026 | Allow | 12 | 2 | 0 | No | No |
| 18948331 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | November 2024 | October 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18377827 | HELPER PLASMID AND METHOD FOR PREPARING RECOMBINANT ADENO-ASSOCIATED VIRUS | October 2023 | September 2025 | Allow | 23 | 1 | 0 | No | No |
| 18255221 | SUSPENSION MODE SEED TRAIN DEVELOPMENT FOR ADHERENT CELLS | May 2023 | December 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 18136774 | REGULATION OF TRANSLATION OF EXPRESSED GENES | April 2023 | February 2026 | Allow | 34 | 0 | 0 | No | No |
| 17789447 | CANCER GENE THERAPY DRUG | June 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17788774 | LOW-SERUM MEDIUM COMPOSITION FOR CULTURING VERO CELLS AND USE THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17843462 | FUSION PROTEIN THAT IMPROVES GENE EDITING EFFICIENCY AND APPLICATION THEREOF | June 2022 | March 2026 | Allow | 45 | 1 | 0 | Yes | No |
| 17784133 | VIABLE TISSSUE FORMS AND METHODS FOR MAKING AND USING SAME | June 2022 | February 2026 | Allow | 44 | 1 | 0 | No | No |
| 17782206 | METHODS OF PREPARING VIRAL VECTORS | June 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17767453 | COMPOSITION FOR AUGMENTING STEMNESS AND USE THEREOF | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17766071 | USE OF HEMATOPOIETIC STEM CELLS IN PREPARATION OF FORMULATION FOR TREATING VIRAL DISEASES | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17765695 | BIOMARKER COMPOSITION FOR PREDICTING THERAPEUTIC EFFECT OF MESENCHYMAL STEM CELLS ON RENAL FIBROSIS | March 2022 | January 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17763991 | LUNG FIBROSIS MODEL AND METHODS OF USING THE SAME | March 2022 | December 2025 | Allow | 45 | 2 | 1 | No | No |
| 17703316 | METHODS OF PRODUCING DECELLULARIZED AND RECELLULARIZED PROSTATE TISSUES AND TREATING BENIGN PROSTATIC HYPERPLASIA OR PROSTATE CANCER | March 2022 | May 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17694715 | COMPOSITIONS CONTAINING EXOSOMES FROM ANIMAL PLACENTA, METHODS FOR PRODUCING THE SAME AND USES THEREOF | March 2022 | December 2024 | Allow | 33 | 1 | 0 | No | No |
| 17753491 | FIBROBLAST AND FIBROBLAST-IMMUNOCYTE COMBINATIONS FOR TREATMENT OF SUBCONCUSSIVE- AND CONCUSSIVE-ASSOCIATED NEUROLOGICAL DAMAGE | March 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17673107 | AUTOLOGOUS STEM CELL VACCINE AND METHODS | February 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17634723 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | February 2022 | January 2026 | Allow | 48 | 2 | 0 | No | No |
| 17627500 | METHOD OF CULTURING MESENCHYMAL STEM CELLS | January 2022 | November 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17576827 | DNA, EXPRESSION VECTOR, TRANSCRIPT, CELL, PHARMACEUTICAL COMPOSITION, AND MEDICINE | January 2022 | October 2025 | Allow | 45 | 2 | 0 | No | No |
| 17626381 | MOSQUITO EGG CRYOPRESERVATION | January 2022 | August 2025 | Allow | 43 | 1 | 0 | No | No |
| 17623493 | METHODS OF FUNCTIONAL VASCULARIZATION OF PANCREATIC ISLETS AND BETA-CELL ORGANOIDS | December 2021 | November 2025 | Allow | 47 | 1 | 1 | No | No |
| 17560595 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING GLYCOGEN STORAGE DISEASE TYPE III | December 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17644931 | NOVEL CANCER ANTIGENS AND METHODS | December 2021 | March 2026 | Allow | 51 | 2 | 1 | No | No |
| 17545262 | PREVENTION OF PROTEIN DISULFIDE BOND REDUCTION | December 2021 | July 2025 | Allow | 43 | 1 | 0 | No | No |
| 17615975 | Oligodendrocyte-derived Extracellular Vesicles for Therapy of Multiple Sclerosis | December 2021 | August 2025 | Allow | 44 | 2 | 0 | No | No |
| 17614900 | Modified NK-92 cells, and therapeutic and diagnostic uses thereof | November 2021 | December 2025 | Allow | 49 | 2 | 1 | No | No |
| 17534594 | INDUCED STEM CELLS | November 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17612441 | CELL-CONTAINING PHARMACEUTICAL COMPOSITION | November 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17612153 | CULTURE CONTAINER FOR CULTURING EPITHELIAL CELLS AND USE THEREOF | November 2021 | October 2025 | Allow | 47 | 2 | 0 | No | No |
| 17610123 | METHODS FOR THE PRODUCTION OF HEPATOCYTES | November 2021 | July 2025 | Allow | 44 | 1 | 0 | No | No |
| 17609170 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | November 2021 | January 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17607138 | METHOD OF INTRODUCING A PLURALITY OF GENE DRIVES INTO A POPULATION | October 2021 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17594602 | ANIMAL FAT-DERIVED EXTRACELLULAR MATRIX, AND PRESERVATION SOLUTION OF ANIMAL FAT-DERIVED EXTRACELLULAR MATRIX | October 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17602980 | ENGINEERED CRY PROTEINS FOR DELIVERY OF THERAPEUTICS | October 2021 | July 2025 | Allow | 45 | 1 | 1 | No | No |
| 17405579 | DERIVATION OF HUMAN MICROGLIA FROM PLURIPOTENT STEM CELLS | August 2021 | March 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17423737 | METHODS AND SYSTEMS FOR PRODUCING AAV PARTICLES | July 2021 | July 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17331551 | METHODS FOR INCREASING EFFICIENCY OF NUCLEASE-INDUCED HOMOLOGY-DIRECTED REPAIR | May 2021 | December 2024 | Allow | 43 | 0 | 1 | Yes | No |
| 17308568 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | May 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17278380 | MAKING AND USING CARDIOPOIETIC CELLS | March 2021 | September 2025 | Allow | 54 | 5 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MOORE, JOHN DAVID works in Art Unit 1638 and has examined 19 patent applications in our dataset. With an allowance rate of 84.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner MOORE, JOHN DAVID's allowance rate of 84.2% places them in the 59% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MOORE, JOHN DAVID receive 1.42 office actions before reaching final disposition. This places the examiner in the 23% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MOORE, JOHN DAVID is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.8% benefit to allowance rate for applications examined by MOORE, JOHN DAVID. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 40.0% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.